Divanadyl pyrophosphate

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Meets generally accepted scientific standards, well documented and acceptable for assessment.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1989

Report date:

1989

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

EPA OPP 81-1 (Acute Oral Toxicity)

GLP compliance:

yes

Test type:

standard acute method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Divanadyl pyrophosphate

EC Number:

407-130-0

EC Name:

Divanadyl pyrophosphate

Cas Number:

65232-89-5

Molecular formula:

(VO)2P2O7

IUPAC Name:

(phosphonooxy)phosphonic acid dihydrate vanadium

Details on test material:

- Physical state: greyish-green powder
- Analytical purity: 100%
- Lot/batch No.: 3883559 A
- Storage condition of test material: room temperature

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River Inc. Wilmington, Massachusetts.
- Age at study initiation: young adults (9-12 weeks).
- Weight at study initiation: males: 256 - 339 g; females: 224 - 264 g;
- Fasting period before study: overnight (approximately 18 hours).
- Housing: individually.
- Diet: Purina Laboratory Chow , #5001, ad libitum.
- Water: tap water, ad libitum.
- Acclimation period: 10-21 days.

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 24 °C
- Humidity (%): 30 - 70 %
- Photoperiod (hrs dark / hrs light): 12 h/ 12 h

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

corn oil

Details on oral exposure:

MAXIMUM DOSE VOLUME APPLIED: 10 ml

Doses:

600, 1200, 2500, 3500, 5000 mg/kg bw.
Initially 5000 mg/kg bw were dosed but due to mortality seen, additional levels were added.

No. of animals per sex per dose:

5

Control animals:

not specified

Details on study design:

- Duration of observation period following administration: 14 days;
- Frequency of observations: twice daily;
- Frequency of weighing: prefast, postfast (just prior to dosing), days 7 and 14;
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight,

Statistics:

Lichfield and Wilcoxon method.

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

911 mg/kg bw

Based on:

test mat.

95% CL:

728 - 1 140

Mortality:

600 mg/kg bw: 1 female died;
1200 mg/kg bw: 3 males and all females died;
2500, 3500 and 5000 mg/kg bw: all animals died;

Clinical signs:

other: Signs seen on the day of dosing in most groups included discharge, fecal staining, soft stool, and hypoactivity. On the day after dosing most animals in most groups showed urinary staining; a few animals had ataxia, hypothermia and prostration. Most survi

Gross pathology:

Postmortem examinations of animals which were found dead revealed a variety of changes, primarily in the lungs and gastrointestinal tract. Some animals which were found dead exhibited changes in the stomach and intestine which were suggestive of an irritant effect (discoloration of walls), and most had apparent test material in the gastrointestinal tract. Several animals had accentuated lobular pattern of the liver. Other changes in animals found dead appeared to represent autolytic alterations or were the result of antemortem stress (testes in the body cavity). Changes in animals sacrificed after 14 days were similar to those seen in control animals.